Beta-blockers and Airways Disease

Not Applicable

Completed

• Conditions: Obstructive airways disease - COPD; Asthma; Respiratory - Chronic obstructive pulmonary disease; Respiratory - Asthma

• Registration Number: ACTRN12605000148673
• Lead Sponsor: Belinda Cochrane

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-08-15
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Acceptance for hospital admission under the cardiology unit of Royal Pince Alfred Hospital for assessment and treatment of an acute cardiac condition

Exclusion Criteria

No exclusion criteria

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Estimation of prevalence of obstructive airways disease amongst the study population[At time of enrolment, prior to hospital discharge, at 6 months and 12 months]

Secondary Outcome Measures

Name	Time	Method
Define cardiologists' prescription practices with regard to beta-blocker medications in patients with obstructive airways disease.[Measurements recorded at time of hospital admission and hospital discharge.];Assess for adverse repsiratory effects of beta-blocker use, over a year's duration, in terms of presence/severity of respiratory symptoms, exacerbations rates, hospital admissions and spirometry performance.[Timing of measurements as defined above under interventions, except for exacerations and hospital admission rates which were assessed at enrolment, at 6 months and at 12 months.]